Brokerages Set Pyxis Oncology, Inc. (NASDAQ:PYXS) PT at $9.20

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) have been given a consensus rating of “Moderate Buy” by the six brokerages that are covering the firm, Marketbeat reports. One analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 year target price among brokers that have covered the stock in the last year is $9.20.

A number of analysts recently weighed in on the stock. Royal Bank of Canada reissued an “outperform” rating and issued a $8.00 target price on shares of Pyxis Oncology in a research note on Wednesday, March 19th. HC Wainwright reiterated a “buy” rating and issued a $5.00 price target on shares of Pyxis Oncology in a research report on Wednesday, March 19th.

Pyxis Oncology Trading Down 2.8 %

Shares of NASDAQ:PYXS opened at $1.06 on Friday. The firm has a market capitalization of $65.29 million, a PE ratio of -1.03 and a beta of 1.11. Pyxis Oncology has a 1-year low of $0.99 and a 1-year high of $6.18. The business’s 50 day moving average is $1.29 and its 200-day moving average is $2.27.

Pyxis Oncology (NASDAQ:PYXS) last posted its quarterly earnings results on Tuesday, March 18th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.01. The business had revenue of $16.15 million for the quarter. On average, sell-side analysts predict that Pyxis Oncology will post -1.04 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in PYXS. Ridgeback Capital Investments L.P. bought a new position in shares of Pyxis Oncology in the fourth quarter worth about $560,000. ProShare Advisors LLC bought a new position in Pyxis Oncology in the 4th quarter worth approximately $26,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in Pyxis Oncology during the 4th quarter worth $228,000. Millennium Management LLC boosted its position in Pyxis Oncology by 53.8% in the 4th quarter. Millennium Management LLC now owns 2,980,906 shares of the company’s stock valued at $4,650,000 after buying an additional 1,043,228 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. increased its stake in shares of Pyxis Oncology by 57.2% in the 4th quarter. Jacobs Levy Equity Management Inc. now owns 601,940 shares of the company’s stock valued at $939,000 after buying an additional 219,100 shares during the period. Institutional investors and hedge funds own 39.09% of the company’s stock.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.